Europe
Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.).
The DEA has reclassified GW Pharmaceutical’s cannabidiol epilepsy treatment Epidiolex as a Schedule V product, which will clear the way for commercialization within the next six weeks.
There has been quite a lot of big news coming out involving cannabis as of late, with much of this news being in regard to clinical trials and government approvals. All of these clinical trials are helping to further our knowledge of cannabis’s potential medical benefits and safety as a medication, and they are opening the way for more research to be done down the line as well.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Geron Corporation, located in Menlo Park, Calif., announced that Janssen Biotech, a Johnson & Johnson company, had terminated their 2014 Collaboration and License Agreement.
System is Fully Integrated with Medtronic’s Market-Leading Imaging and Navigation Technology to Transform Posterior Cervical Spine Surgery
Quanticate, has announced that it has partnered with CluePoints™ to utilize their software to drive the statistical analysis to perform data integrity checks on all types of monitoring and investigator site data as part of its new Data Quality Oversight service that enables centralized statistical monitoring, in response to the amendments to the ICH Good Clinical Practice (GCP) E6(R2) guidelines.
Cobra Biologics, GE Healthcare and Centre for Process Innovation Collaborate to Advance Gene Therapy
Innovate UK funded project supports development of scalable, cost effective production of regenerative medicines
Motif Bio plc today announced unaudited financial results for the half year ended June 30, 2018 and reported on its progress year to date.
Lonza is holding a series of events as part of this year’s Capital Markets Day from 24-26 September in Zurich and Visp (CH).
PRESS RELEASES